5 Einträge von 12 mit haemophilia program
www.medicaljoyworks.com
Datum der Indexierung 05.05.2021 07:23:52
Subdomain:
extern (outbound) Link/Domain 2 in www.medicaljoyworks.com
intern (inbound) Link/Domain www.medicaljoyworks.com
Alle Links in alle Links in www.medicaljoyworks.com
HTML Description Thrombotic References
Kombination Keywords protein note | from thrombophilia | available that | deficiency levels | online this | viewed acute | thrombosis therapy | venous should | patients warfarin | with diagnosis |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia [online] 2008 Nov, 14(6):1214-21 [viewed 19 May 2014] Available from: doi:10.1111/j.1365-2516.2008.01838.x WILBUR J, SHIAN B. Diagnosis of deep venous thrombosis and pulmonary embolism. Am Fam Physician [online] 2012 Nov 15, 86(10):913-9 Program [online] 2008:228-35 [viewed 19 May 2014] Available from: doi:10.1182/asheducation-2008.1.228 TOVEY C, WYATT S. Diagnosis, investigation, and management of deep vein thrombosis BMJ [online] 2003 May 31, 326(7400):1180-1184
Text Inhalt Text aus URL
Log Metriken 646380
Subdomain:
extern (outbound) Link/Domain 2 in www.medicaljoyworks.com
intern (inbound) Link/Domain www.medicaljoyworks.com
Alle Links in alle Links in www.medicaljoyworks.com
HTML Description Thrombotic References
Kombination Keywords protein note | from thrombophilia | available that | deficiency levels | online this | viewed acute | thrombosis therapy | venous should | patients warfarin | with diagnosis |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia [online] 2008 Nov, 14(6):1214-21 [viewed 19 May 2014] Available from: doi:10.1111/j.1365-2516.2008.01838.x WILBUR J, SHIAN B. Diagnosis of deep venous thrombosis and pulmonary embolism. Am Fam Physician [online] 2012 Nov 15, 86(10):913-9 Program [online] 2008:228-35 [viewed 19 May 2014] Available from: doi:10.1182/asheducation-2008.1.228 TOVEY C, WYATT S. Diagnosis, investigation, and management of deep vein thrombosis BMJ [online] 2003 May 31, 326(7400):1180-1184
Text Inhalt Text aus URL
Log Metriken 646380
www.cslbehring.ch
Datum der Indexierung 05.05.2021 02:08:20
erkannte Namen Alex Gertsch | Gérard Jenni | Amir Abrashi | Georg Ptak | Jérôme Gremaud | Bill Mezzanotte | Gene Therapy | Nat Rev | Tim Frei | Lia Huwiler |
weitere Namen in www.cslbehring.ch 11
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=en-us&hash=AFE5B4AC5CAAF019462A6FA5337D981C7508AAE6
Kombination Keywords promise research | driven therapy | with fluad | cidp cell | phase japan | anti data | transplant market | hizentra study | privigen products | clinical patients |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia Bill Campbell • Q&A – Break – • Clinical Development Overview Bill Mezzanotte • Commercial Overview Specialty, Transplant, CSL112 Bill Campbell • Summary Bill Mezzanotte • Q&A | Driven by Our Promise™4 | Driven by Our Promise™4 Introducti program completed | Driven by Our Promise™16 | Driven by Our Promise™16 Successful completion of AFLURIA QIV program Percentage of subjects with fever above 38ºC AFLURIA Fluzone Fluzone USF0736 AFLURIA TIV Pooled USF0736 USF0629 N
Text Inhalt Text aus URL
Log Metriken 446265
erkannte Namen Alex Gertsch | Gérard Jenni | Amir Abrashi | Georg Ptak | Jérôme Gremaud | Bill Mezzanotte | Gene Therapy | Nat Rev | Tim Frei | Lia Huwiler |
weitere Namen in www.cslbehring.ch 11
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=en-us&hash=AFE5B4AC5CAAF019462A6FA5337D981C7508AAE6
Kombination Keywords promise research | driven therapy | with fluad | cidp cell | phase japan | anti data | transplant market | hizentra study | privigen products | clinical patients |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia Bill Campbell • Q&A – Break – • Clinical Development Overview Bill Mezzanotte • Commercial Overview Specialty, Transplant, CSL112 Bill Campbell • Summary Bill Mezzanotte • Q&A | Driven by Our Promise™4 | Driven by Our Promise™4 Introducti program completed | Driven by Our Promise™16 | Driven by Our Promise™16 Successful completion of AFLURIA QIV program Percentage of subjects with fever above 38ºC AFLURIA Fluzone Fluzone USF0736 AFLURIA TIV Pooled USF0736 USF0629 N
Text Inhalt Text aus URL
Log Metriken 446265
www.cslbehring.ch
Datum der Indexierung 05.05.2021 16:44:47
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=fr-fr&hash=6A9CD360662B6CDEDCAE1B016E11BD8F68ED4E2B
Kombination Keywords haemophilia program | phase market | specialty rviii | study immunoglobulins | products prophylaxis | patients research | with breakthrough | global medicines | development rix-fp | clinical bleeding |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Breakthrough Medicines • CSL112 Clinical Development Charmaine Gittleson • Influenza Vaccines R&D Andrew Cuthbertson • Summary • Q&A Global 4 Introduction Programs* P. gingivalis/POD OH-CRC/Sanofi* CSL689 rVIIa-FP Inhibitors Privigen ® CIDP KcentraTM US Bleeding /Surgery Hizentra® Japan Partnered Vaccine Programs* Partnered Vaccine Programs* FXIIa Antagonist Hizentra® biweekly New P
Text Inhalt Text aus URL
Log Metriken 446196
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=fr-fr&hash=6A9CD360662B6CDEDCAE1B016E11BD8F68ED4E2B
Kombination Keywords haemophilia program | phase market | specialty rviii | study immunoglobulins | products prophylaxis | patients research | with breakthrough | global medicines | development rix-fp | clinical bleeding |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Breakthrough Medicines • CSL112 Clinical Development Charmaine Gittleson • Influenza Vaccines R&D Andrew Cuthbertson • Summary • Q&A Global 4 Introduction Programs* P. gingivalis/POD OH-CRC/Sanofi* CSL689 rVIIa-FP Inhibitors Privigen ® CIDP KcentraTM US Bleeding /Surgery Hizentra® Japan Partnered Vaccine Programs* Partnered Vaccine Programs* FXIIa Antagonist Hizentra® biweekly New P
Text Inhalt Text aus URL
Log Metriken 446196
www.cslbehring.ch
Datum der Indexierung 05.05.2021 03:20:38
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=en-us&hash=79E0F9AF1E7E5E6CB7374E2A0C6C58DCC101488D
Kombination Keywords phase japan | global efficacy | specialty clinical | breakthrough research | haemophilia briefing | medicines investor | products privigen | immunoglobulins afstyla | with market | afluria development |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Breakthrough Medicines • CSL112 Clinical Development Charmaine Gittleson • CSL112 Commercial Opportunities Bob Repella • Seqirus R&D Russell Basser • Summ Programs* P. gingivalis/POD OH-CRC CSL689 rVIIa-FP Inhibitors KCENTRA® US Bleeding / Surgery Partnered Vaccine Programs* Partnered Vaccine Programs* CSL312 Anti-FXIIa CSL362 IL-3R* AML Janssen CSL334 IL-13R* ASLAN CSL689 rVIIa-FP
Text Inhalt Text aus URL
Log Metriken 446268
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=en-us&hash=79E0F9AF1E7E5E6CB7374E2A0C6C58DCC101488D
Kombination Keywords phase japan | global efficacy | specialty clinical | breakthrough research | haemophilia briefing | medicines investor | products privigen | immunoglobulins afstyla | with market | afluria development |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Breakthrough Medicines • CSL112 Clinical Development Charmaine Gittleson • CSL112 Commercial Opportunities Bob Repella • Seqirus R&D Russell Basser • Summ Programs* P. gingivalis/POD OH-CRC CSL689 rVIIa-FP Inhibitors KCENTRA® US Bleeding / Surgery Partnered Vaccine Programs* Partnered Vaccine Programs* CSL312 Anti-FXIIa CSL362 IL-3R* AML Janssen CSL334 IL-13R* ASLAN CSL689 rVIIa-FP
Text Inhalt Text aus URL
Log Metriken 446268
www.cslbehring.ch
Datum der Indexierung 05.05.2021 04:36:59
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=fr-fr&hash=494FDD9185B1042615BEEBFB38FFDCB1D72C821B
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia and Specialty Products – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Program Sickle Cell Disease • Group of disorders caused by abnormal beta-globin gene resulting in sickled red cells • Average life expectancy in the developed world is 40 – 60yrs • High unmet need • Total SCD patients: 155,000 (US
Text Inhalt Text aus URL
Log Metriken 446193
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=fr-fr&hash=494FDD9185B1042615BEEBFB38FFDCB1D72C821B
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Haemophilia and Specialty Products – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Program Sickle Cell Disease • Group of disorders caused by abnormal beta-globin gene resulting in sickled red cells • Average life expectancy in the developed world is 40 – 60yrs • High unmet need • Total SCD patients: 155,000 (US
Text Inhalt Text aus URL
Log Metriken 446193